Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVXL

DatePrice TargetRatingAnalyst
12/6/2022$16.00 → $11.00Overweight → Neutral
Cantor Fitzgerald
6/23/2022$40.00Buy
Berenberg
2/2/2022$39.00 → $42.00Buy
HC Wainwright & Co.
9/23/2021$35.00Buy
BTIG Research
6/28/2021$25.00 → $39.00Buy
HC Wainwright & Co.
More analyst ratings

$AVXL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

    NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:45 PM (ET) on Monday, April 7th, 2025. A live audio webcast will be accessible th

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

    NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AVXL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AVXL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVXL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVXL
SEC Filings

See more

$AVXL
Leadership Updates

Live Leadership Updates

See more
  • Anavex Life Sciences Announces Expansion of Leadership Team

    NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline

    LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing c

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AVXL
Financials

Live finance-specific insights

See more
  • Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

    NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first fiscal quarter on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Follow

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains de

    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AVXL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more